Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. has announced a change in its major holdings, with BlackRock, Inc. adjusting its voting rights in the company. As of May 13, 2025, BlackRock holds 7.61% of the total voting rights in MaxCyte, a slight decrease from its previous position. This adjustment in holdings could impact MaxCyte’s shareholder dynamics and influence future strategic decisions, reflecting BlackRock’s ongoing portfolio management strategy.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on providing cell-engineering platforms for cell-based research and biomanufacturing. The company is known for its proprietary flow electroporation technology, which is used by leading pharmaceutical and biotechnology companies to accelerate the development of cell therapies and gene editing applications.
See more insights into MXCT stock on TipRanks’ Stock Analysis page.